Last reviewed · How we verify
NCT04466696
Feasibility of ERAS Protocol in T4 Colorectal Cancer Patients
trial testing ERAS protocol in T4 Colorectal Cancer in 82 participants. Completed in 7 July 2020.
30 May 2020
Quick facts
| Lead sponsor | University of Rome Tor Vergata |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 82 |
| Start date | 1 January 2016 |
| Primary completion | 30 May 2020 |
| Estimated completion | 7 July 2020 |
Drugs / interventions tested
- ERAS protocol
Conditions studied
- T4 Colorectal Cancer — all drugs for T4 Colorectal Cancer →
- ERAS — all drugs for ERAS →
- Colon Cancer — all drugs for Colon Cancer →
- Fast Track Protocol — all drugs for Fast Track Protocol →
Sponsor
University of Rome Tor Vergata
Who can join
18 and older, any sex, with T4 Colorectal Cancer or ERAS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients diagnosed with T4 colorectal cancer represent a specific subgroup of colorectal patients, frequently composed of fragile patients whose advanced nature of the disease often requires a multi organ resection by an open surgery approach and frequently leads to higher intra/postoperative complication.Those characteristics makes them to be considered less suitable for ERAS protocol, especially regarding an expected difficult compliance to postoperative items. The impact of enhanced recovery program on postoperative outcomes in this subset of patients has never been addressed in literature, in fact most of studies either excluded T4 patients due to higher rates of complication or adopted an homogeneous patient sampling analizing all stage colorectal cancer together. Our aim is to investigate the feasibility of ERAS protocol in T4 colorectal patient, primary outcome was to compare postoperative lenght of stay between T4 colorectal patients treated with ERAS protcol and those treated with standard of care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility and outcomes of ERAS protocol in elective cT4 colorectal cancer patients: results from a single-center retrospective cohort study.
Bellato V, An Y, Cerbo D, Campanelli M, et al · · 2021 · cited 11× · PMID 34215273 · DOI 10.1186/s12957-021-02282-7
Verify or expand the search:
- PubMed search for NCT04466696
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ERAS protocol
Trials testing the same drug.
- NCT06984952 — Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy · NA · recruiting
- NCT07087366 — Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital · NA · recruiting
- NCT07232394 — Early Feeding and Mobilization in Thoracic Surgery · NA · completed
- NCT06729736 — Implementation of the ERAS in Colorectal Cancer Patients: a Single Arm Study · NA · enrolling by invitation
- NCT06489288 — ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer · NA · active not recruiting
Other recruiting trials for T4 Colorectal Cancer
Currently open trials in the same condition.
- NCT06958926 — A Translational Study for Locoregional Recurrence of T4 Colon Cancer · recruiting
Other University of Rome Tor Vergata trials
Trials by the same sponsor.
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT07313358 — 10119473 -VIROMARKERS HDV Biomarkers Study · not yet recruiting
- NCT07286461 — VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol · not yet recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06711744 — ISQ Differences Between Different Implants in Post-extraction Sockets · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04466696 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rome Tor Vergata
- Last refreshed: 29 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04466696.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing